Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.37 |
| ▸ | KDM5C | P41229 | 3/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.37 |
| ▸ | KDM6B | O15054 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.32 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.31 |
| ▸ | GABRD | O14764 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15470670 | 0.81 | EGLN1 (0.42) | TSHREGLN1KDM5CPHF8KDM2A | |
| SCHEMBL17506142 | 0.79 | EGLN1 (0.41) | TSHREGLN1KDM5CPHF8KDM2A | |
| SCHEMBL11679497 | 0.79 | EGLN1 (0.41) | TSHREGLN1KDM5CPHF8KDM2A | |
| SCHEMBL3799285 | 0.78 | EGLN1 (0.39) | TSHREGLN1KDM5CPHF8KDM2A | |
| SCHEMBL3031454 | 0.75 | EGLN1 (0.37) | TSHREGLN1KDM5CPHF8KDM2A | |
| SCHEMBL1134608 | 0.75 | EGLN1 (0.43) | TSHREGLN1KDM5CPHF8KDM2A | |
| SCHEMBL644570 | 0.75 | EGLN1 (0.43) | TSHREGLN1KDM5CPHF8KDM2A | |
| SCHEMBL27448246 | 0.75 | EGLN1 (0.43) | EGLN1KDM5CPHF8KDM2AKDM6B | |
| SCHEMBL23192558 | 0.73 | EGLN1 (0.42) | TSHREGLN1KDM5CPHF8KDM2A | |
| SCHEMBL30127186 | 0.73 | EGLN1 (0.42) | TSHREGLN1KDM5CPHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512158-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | NEWLINK GENETICS CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2089051-B1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9090643-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | NEWLINK GENETICS CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-8916169-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | NEWLINK GENETICS CORPORATION (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130178613-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NewLink Genetics Corp. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130164318-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NewLink Genetics Corp. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164319-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NewLink Genetics Corp. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8357777-B2 | Enhanced immunogenicity of tumor associated antigens by addition of αgal epitopes | NEWLINK GENETICS (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120003251-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2012-01-05 | — | — | US | disclosed |
| US-7998486-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes | NEWLINK GENETICS CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2089051-A2 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | Newlink Genetics (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090060930-A1 | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes | NEWLINK GENETICS | 2009-03-05 | — | — | US | disclosed |
| WO-2008057235-A9 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008057235-A2 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164319-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, FUT5, FUT6 | TSHR 1662/4885EGLN1 3735/4885KDM5C 2913/4885 |
| US-20130178613-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, FUT5, FUT6 | TSHR 1662/4885EGLN1 3735/4885KDM5C 2913/4885 |
| US-20090060930-A1 | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes | ENGASE, FUT5, FUT6 | TSHR 1662/4885EGLN1 3735/4885KDM5C 2913/4885 |
| US-20120003251-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, GALE, FUT5 | TSHR 2080/4885EGLN1 3084/4885KDM5C 2053/4885 |
| US-20130164318-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, FUT5, FUT6 | TSHR 1662/4885EGLN1 3735/4885KDM5C 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.